Ignite Creation Date:
2025-12-24 @ 1:07 PM
Ignite Modification Date:
2026-02-03 @ 6:20 AM
Study NCT ID:
NCT02061761
Status:
COMPLETED
Last Update Posted:
2023-03-24
First Post:
2014-02-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
Sponsor:
Bristol-Myers Squibb
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hematologic Neoplasms | View |